May 15, 2014 / 3:40 AM / in 4 years

India's Sun Pharma settles Novartis lawsuit over leukemia drug

MUMBAI, May 15 (Reuters) - Sun Pharmaceutical Industries Ltd said it was allowed to launch a generic version of Novartis’ leukemia drug Gleevec in the United States on Feb. 1, 2016, under a settlement agreement between the two companies.

The other terms of the agreement are confidential, Sun Pharma said in a statement on Thursday.

Sun Pharma’s subsidiary holds a tentative approval from the U.S Food and Drug Administration for a generic version of Gleevec. As per IMS data, Gleevec had annual sales of about $2 billion in the United States, Sun said. (Reporting by Aradhana Aravindan; Editing by Anupama Dwivedi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below